ArticlePloS one2012
Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Phage therapy for intestinal infections: efficacy, challenges, and future directions in translational research.Frontiers in microbiology · 2025Review
- Positive and negative aspects of bacteriophages and their immense role in the food chain.NPJ science of food · 2024Review
- Bacteriophage Production in Compliance with Regulatory Requirements.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Article
- Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Screening of Anorectal and Oropharyngeal Samples Fails to Detect Bacteriophages InfectingAntibiotics (Basel, Switzerland) · 2022Article
- Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology.Microbial cell factories · 2021Article
- Bacteriophages Against Pathogenic Bacteria and Possibilities for Future Application in Africa.Infection and drug resistance · 2021Review
- Phage Therapy in the Year 2035.Frontiers in microbiology · 2020Article
- Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives.Dermatology and therapy · 2019Review
- Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?International journal of molecular sciences · 2019Review
- Characterization and Genomic Study of Phage vB_EcoS-B2 Infecting Multidrug-ResistantFrontiers in microbiology · 2018Article
- Public Health Research Resulting from One of the World's Largest Outbreaks Caused by Entero-HemorrhagicFrontiers in public health · 2017Review
- Bacteriophages as Potential Treatment for Urinary Tract Infections.Frontiers in microbiology · 2016Article
- Quality and safety requirements for sustainable phage therapy products.Pharmaceutical research · 2015Article
- Public health evolutionary biology of antimicrobial resistance: priorities for intervention.Evolutionary applications · 2015Article
- A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.Virulence · 2014Review
- Taking bacteriophage therapy seriously: a moral argument.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2011, a novel strain of O104:H4 Escherichia coli caused a serious outbreak of foodborne hemolytic uremic syndrome and bloody diarrhea in Germany. Antibiotics were of questionable use and 54 deaths occurred. Candidate therapeutic bacteriophages that efficiently lyse the E. coli O104:H4 outbreak strain could be selected rather easily from a phage bank or isolated from the environment. It is argued that phage therapy should be more considered as a potential armament against the growing threat of (resistant) bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.